This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aortic valve replacement (TAVR). Our study aimed to use an innovative wearable acoustic cardiography (ACG) device to diagnose SLT as an alternative option.
This innovation promises to transform treatment for life-threatening vascular conditions like thrombosis. Researchers at the TechMed Center of the University of Twente and Radboud University Medical Center have removed blood clots with wireless magnetic robots.
However, innovation in MHV design faces several challenges: strict performance and biocompatibility requirements, limited understanding of the mechanisms underlying MHV thrombosis, and a lack of effective testing methodologies to assess how design variations impact both hemodynamic performance and thrombogenicity of MHVs.
The results of our validation studies show this innovative test demonstrates outstanding intra (2 percent) and inter (10 percent) test variation, well below the current FDA guidance (25 percent)," said Dr. David Schneider Prolocor Co-Founder and Chief Science Officer. tim.hodson Tue, 09/10/2024 - 13:34 Sept. 5,2024 - Prolocor, Inc.
The catheter is designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of the legs or abdomen that can have a life-threatening impact if left untreated. tim.hodson Mon, 03/24/2025 - 15:48 March 24, 2025 Imperative Care, Inc. recently announced U.S.
It enrolled 162 subjects at 30 centers with three patient populations – non-thrombotic iliac vein lesion (NIVL), post-thrombotic syndrome (PTS) and acute deep vein thrombosis (aDVT). Current and future burden of venous thrombosis: Not simply predictable. J Thromb Haemost 2014; 12: 1580–90. 2] Scheres LJJ, Lijfering WM, Cannegieter SC.
The innovative double balloon catheter Inflation across the the mechanical prosthetic valve is possible. It is to be noted if the obstruction is due to pannus , risk of thrombosis is almost nil and safety of prosthetic balloon valvuloplasty is almost ensured.(Of Of course with risk of device leaflet damage ) 5.As
Innovative trial design, data sharing, and collaborative efforts between academia and industry will be essential. Improved recognition of biomarker research and a greater emphasis on mechanistic evidence can better equip clinicians to deal with the uncertainty that defines the practice of thrombosis medicine.
However, there are shortcomings associated with LVAD implantation: complications include infection, blood clotting (thrombosis), stroke and bleeding. Through a new four-year, $7.8 million Department of Defense grant awarded to the Georgia Institute of Technology (Georgia Tech), Yaxin Wang, PhD (seated left), O.H.
proposed an innovative thromboembolic stroke model in mice where murine thrombin is injected into the M2 segment of the middle cerebral artery (MCA) to induce arterial thrombosis. It emerged as a sensitive but versatile and translationally tool for evaluating pharmacological efficacy and safety of innovative drugs.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content